Ribavirin
Chronic Hepatitis b
Huashan HospitalSmall moleculePhase 4 / ApprovedDormant
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 89/ 100
Competitive context
3 Active assets in the Chronic Hepatitis b cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pegylated Interferon Alpha2A Huashan Hospital | Phase 4 | BB |
Diammonium Glycyrrhizinate Cttq | Phase 4 | BB |
Empagliflozin The University of Hong Kong | Phase 4 | BB |
Peginterferon First Affiliated Hospital of Wenzhou Medical University | Phase 4 | BB |
Magnesium Isoglycyrrhizinate Cttq | Phase 4 | BB |
Tenofovir Alafenamide Ningbo No.2 Hospital | Early Phase 1 | C |
Same molecule, other indications
Ribavirin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →